| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.1M | — | -17.4% |
| SG&A Expense | $2.0M | — | -18.6% |
| Operating Income | -$4.1M | — | +18.0% |
| Net Income | -$3.8M | — | +14.5% |
| EPS (Basic) | -$5.89 | — | -2577.3% |
| EPS (Diluted) | -$5.89 | — | -2577.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.6M | -15.3% | -11.6% |
| Short-term Investments | $22.3M | -11.2% | -38.0% |
| Current Assets | $25.5M | -11.6% | -35.4% |
| Total Assets | $26.1M | -11.7% | -35.7% |
| Current Liabilities | $2.1M | +1.0% | +29.0% |
| Total Liabilities | $2.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.2M | — | +19.4% |
| Investing Cash Flow | $2.8M | — | -46.7% |
| +3.5% |
| Stockholders' Equity | $23.7M | -12.5% | -38.0% |